TVTX — Travere Therapeutics, Inc.

Summary of Travere Therapeutics Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total U.S. Net Product Sales: $124.5 million, reflecting strong year-over-year growth.
• FILSPARI Sales: Approximately $105.2 million, an 88% increase year-over-year, despite challenges from typical beginning-of-year insurance resets and fewer revenue recognition days.
• Thiola and Thiola EC Sales: Contributed $19.3 million.
• Net Loss: $37.1 million ($0.40 per share), improved from a net loss of $41.2 million ($0.47 per share) in Q1 2025.
• Non-GAAP Adjusted Net Income: $4.1 million ($0.05 per share), compared to a loss of $16.9 million ($0.19 per share) in the prior year.
• Cash Position: Approximately $352 million in cash, cash equivalents, and marketable securities as of March 31, 2026.

2. Strategic Updates and Business Highlights

• FDA Approval: FILSPARI received full FDA approval for FSGS, marking it as the first and only approved treatment for this condition.
• Patient Reach: Over 100,000 patients in the U.S. are estimated to be eligible for FILSPARI across IgA nephropathy and FSGS, with a projected peak sales opportunity of $3 billion.
• Commercial Performance: Record demand for FILSPARI in IgA nephropathy with 993 new patient start forms in Q1 2026.
• Pipeline Advancement: Dosing of the first patient in the Phase III HARMONY study of pegtibatinase for classical homocystinuria (HCU) has commenced, with top-line results expected in 2027.

3. Forward Guidance and Outlook

• Growth Expectations: Continued strong demand in IgA nephropathy is anticipated to drive sustained revenue growth, with FSGS expected to further enhance the top-line trajectory.
• Operational Funding: The company believes it is well-positioned to fund operations and invest in key priorities, including the commercialization of FILSPARI and the advancement of the HARMONY study.

4. Bad News, Challenges, or Points of Concern

• Increased Operating Expenses: R&D expenses rose to $57.1 million, and SG&A expenses increased to $80.3 million, primarily due to investments in FILSPARI's launch and ongoing clinical studies.
• Market Competition: There is ongoing competitive pressure from other treatments in the IgA nephropathy space, including potential new entrants that could impact market dynamics.
• Education Needs: There is a need for continued education among physicians regarding FILSPARI's indication, particularly concerning nephrotic syndrome, which could affect adoption rates.

5. Notable Q&A Insights

• FSGS Launch: Early feedback indicates a faster uptake for FILSPARI in FSGS compared to IgA nephropathy, attributed to high unmet need and existing physician familiarity with the drug.
• Payer Dynamics: Initial reimbursement approvals for FSGS were received quickly, with higher first-pass approval rates than seen during the IgA nephropathy launch.
• Physician Education: There is a need to clarify the distinction between nephrotic syndrome and nephrotic-range proteinuria to ensure appropriate prescribing practices.
• Patient Start Forms (PSFs): The company is seeing both existing FILSPARI prescribers and new prescribers for FSGS, indicating a potential halo effect benefiting both indications.

Overall, Travere Therapeutics reported a robust start to 2026, driven by strong sales of FILSPARI and strategic advancements in its pipeline, while also facing challenges related to education and competition in the market.